An Open Label Study of CM-AT for the Treatment of Children With Autism
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 300
Summary
- Conditions
- Autism
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 3 years and 17 years
- Gender
- Both males and females
Description
Autism is clearly a significant cause of disability in the pediatric population. Treatment is based on the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a granulated powder taken three times daily.
Autism is clearly a significant cause of disability in the pediatric population. Treatment is based on the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a granulated powder taken three times daily.
Tracking Information
- NCT #
- NCT02649959
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Deborah Pearson, PhD The University of Texas Health Science Center, Houston Principal Investigator: Robert Hendren, DO University of California, San Francisco
Get Well Soon